LianBio Reports Fourth Quarter and Full Year 2021 Financial

Phase 3 registrational trial of mavacamten in Chinese patients with symptomatic obstructive hypertrophic cardiomyopathy (oHCM) ongoing Mavacamten granted...

Related Keywords

China ,Hainan Province ,Hainan ,Shanghai ,Chinese ,Susan Silbermann ,Jesse Wu ,Michael Humphries ,Bristol Myers Squibb ,Yizhe Wang ,Drug Administration ,Products Administration Of Hainan Province ,Exchange Commission ,Clinical Development Updates ,Research Development Expenses ,National Medical Products Administration ,Boao Lecheng International Medical Tourism Pilot Zone ,Health Commission ,Patient Program ,Chief Executive Officer ,Greater China ,Business Highlights ,Drug Evaluation ,Breakthrough Therapy Designation ,Medical Products Administration ,Named Patient Program ,Chief Scientific Advisor ,Anticipated Milestones Expected ,Prescription Drug User Fee Act ,New Drug Application ,Redeemable Convertible Preferred Shares ,Shareholder Equity ,Nasdaq Lian ,Lianbio ,Qian ,